2010, Food and Drug Administration, Patients and Specialization

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2010

Food and Drug Administration

Patients

Specialization

For rare disease patients in Mainland China, hope of greater access to treatment

Clarivate

MAY 24, 2022

Recent policy and regulatory moves have begun to sketch out a framework for rare disease drug approvals in the country, but obstacles to approvals and patient access remain. Mainland China has taken significant steps toward improving access to treatment for its estimated 20 million rare disease patients in recent years. [1]

Patients

Patients Food and Drug Administration Marketing Pharma

Kamada’s Glassia receives marketing authorisation from Swissmedic

Pharmaceutical Technology

MAY 17, 2023

To ensure wide access to eligible patients, we are excited to partner with the IDEOGEN Group, a company focused on the commercialisation of speciality medicines for rare diseases across Europe.” In 2010, the US Food and Drug Administration approved Glassia for the same indication.

Marketing

Marketing Food and Drug Administration Specialization Food

Pharma Rep Focus

For rare disease patients in Mainland China, hope of greater access to treatment

Kamada’s Glassia receives marketing authorisation from Swissmedic

Stay Connected